Stage IV Non-Small Cell Lung Cancer without Driver Alterations
Key Points
Key Points
This clinical practice guideline update addresses two overarching clinical questions:
- What are the most effective first-line treatment options for patients with stage IV NSCLC without driver alterations, based on cancer subtype?
- What are the most effective second-line and subsequent treatment options for patients with stage IV NSCLC without driver alterations based on cancer subtype?
Treatment
...eatment...
...For recommendations with multiple treatment o...
...linical Question 1: What are the most effective f...
...uamous Cell Carcinoma (Non-SCC)...
...ith programmed death-ligand 1 or progra...
.... For patients with a programmed death-liga...
...ents with a programmed death-ligand 1 or progr...
...s with a programmed death-ligand 1 or progr...
...or patients with a programmed death-ligand 1...
...r patients with a programmed death-ligand 1 o...
...s with a programmed death-ligand 1 o...
...s with PD-L1 expression TPS, 1–49%...
...patients with PD-L1 expression TP...
...8. For patients with PD-L1 expressio...
...patients with PD-L1 expression TPS, 1–49%,...
...ents with PD-L1 expression TPS, 1–49%...
...nts with PD-L1 expression TPS, 1–49%...
...ts who are ineligible for or decline t...
...s with unknown or negative PD-L1 expression, TPS...
...ients with unknown or negative PD-L1 expre...
...ents with unknown or negative PD-L...
...atients with unknown or negative PD-L1 expr...
...nts with unknown or negative PD-L1 express...
...atients with unknown or negative PD-L1 expressio...
...s Cell Carcinoma (SCC)...
Patients with PD-L1 expression, TP...
...1. For patients with PD-L1 expression,...
...atients with PD-L1 expression, TPS ≥50%,...
...For patients with PD-L1 expression, TPS ≥5...
3.4. For patients with PD-L1 expression,...
....5. For patients with PD-L1 expressi...
...PD-L1 expression TPS, 1–49%:...
...patients with PD-L1 expression TPS,...
.... For patients with PD-L1 expression TPS,...
...patients with PD-L1 expression TPS, 1–49%, cli...
...patients with PD-L1 expression TPS, 1–49%,...
...0. For patients with PD-L1 expression T...
...h unknown or negative PD-L1 expression, TPS...
...patients with unknown or negative PD-L1 expre...
...tients with unknown or negative PD-L1 expre...
...atients with unknown or negative PD-L1 e...
...ts with unknown or negative PD-L1...
...ts with Unspecified Histo...
...ts with unknown or negative PD-L1 expression, TPS...
...For patients with unknown or negative PD-L1 expr...
....7. For patients with unknown or negative...
...zumab should be avoided for patients with squamous...
...with contraindications to bevacizumab:...
Patients with Unspecifie...
...evacizumab should be avoided for patien...
...bevacizumab given with pemetrexed has no surviva...
...on 2: What are the most effective seco...
...previously treated with immune checkpoint ther...
...ents previously treated with immune check...
...previously treated with chemotherapy and immun...
...In patients previously treated wit...
...previously treated with chemotherapy and immune c...
...1. Second-Line and Subsequent Treatment Opti...
...First-Line Treatment Options for Patients With S...
...rst-Line Treatment Options for Patie...